Proteomics International Laboratories Ltd
ASX:PIQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
AU |
|
M
|
Mediaco Holding Inc
NASDAQ:MDIA
|
US |
|
Netscout Systems Inc
NASDAQ:NTCT
|
US |
|
Phoenix Tours International Inc
TWSE:5706
|
TW |
|
Willdan Group Inc
NASDAQ:WLDN
|
US |
|
Dare Bioscience Inc
NASDAQ:DARE
|
US |
|
ON24 Inc
NYSE:ONTF
|
US |
|
M
|
Monsenso A/S
CSE:MONSO
|
DK |
|
Ultra Electronics Holdings PLC
LSE:ULE
|
UK |
|
WD-40 Co
NASDAQ:WDFC
|
US |
Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bio-analytical services. The firm specializes in proteomics, the study of the structure and function of proteins. The firm focuses on developing and commercializing diagnostic tests for chronic diseases. The firm operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. PromarkerD is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Analytical Services includes proteomics-based technology platform, used to test, and validate the protein composition of a wide and varied range of products.
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bio-analytical services. The firm specializes in proteomics, the study of the structure and function of proteins. The firm focuses on developing and commercializing diagnostic tests for chronic diseases. The firm operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. PromarkerD is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Analytical Services includes proteomics-based technology platform, used to test, and validate the protein composition of a wide and varied range of products.
